Bionano Genomics (NASDAQ:BNGO – Get Free Report)‘s stock had its “sector perform” rating reaffirmed by Scotiabank in a note issued to investors on Wednesday, Benzinga reports. They presently have a $1.00 price target on the stock, down from their previous price target of $6.00. Scotiabank’s price objective suggests a potential upside of 95.08% from the company’s previous close.
Separately, BTIG Research dropped their price target on shares of Bionano Genomics from $3.00 to $2.00 and set a “buy” rating for the company in a research report on Thursday, May 16th.
View Our Latest Report on Bionano Genomics
Bionano Genomics Stock Down 1.8 %
Institutional Trading of Bionano Genomics
A number of institutional investors have recently modified their holdings of BNGO. Armistice Capital LLC acquired a new position in Bionano Genomics during the second quarter valued at approximately $1,138,000. Cetera Advisors LLC acquired a new position in shares of Bionano Genomics during the 1st quarter valued at $163,000. Virtu Financial LLC purchased a new stake in Bionano Genomics during the 1st quarter worth $36,000. Price T Rowe Associates Inc. MD increased its holdings in Bionano Genomics by 123.6% in the 1st quarter. Price T Rowe Associates Inc. MD now owns 70,370 shares of the company’s stock valued at $79,000 after purchasing an additional 38,900 shares in the last quarter. Finally, GSA Capital Partners LLP raised its position in Bionano Genomics by 532.7% in the first quarter. GSA Capital Partners LLP now owns 549,789 shares of the company’s stock valued at $610,000 after purchasing an additional 462,887 shares during the period. Hedge funds and other institutional investors own 11.35% of the company’s stock.
About Bionano Genomics
Bionano Genomics, Inc provides genome analysis software that enables genomics labs to analyze and interpret data across a range of platforms to generate informative data visualizations for streamlined and simple reporting of causal variants. It offers Saphyr, a sample-to-result solution for structural variation analysis by optical genome mapping for genome analysis and understanding of genetic variation and function; Saphyr instrument, a single-molecule imager; Saphyr Chip, a consumable that packages the nanochannel arrays for DNA linearization; and Bionano Prep Kits and DNA labeling kits, which provide the reagents and protocols for extracting and labeling ultra-high molecular weight DNA.
Read More
- Five stocks we like better than Bionano Genomics
- 3 Grocery Stocks That Can Help Take a Bite Out of Inflation
- Sleeper AI-Winner Ambarella Will More Than Triple in PriceĀ
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Gold vs. Silver: Which Is the Better Investment in the New Cycle?
- Energy and Oil Stocks Explained
- 3 Best Growth Stocks to Own for the Next 10 Years
Receive News & Ratings for Bionano Genomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionano Genomics and related companies with MarketBeat.com's FREE daily email newsletter.